Kaletra lopinavir/ritonavir: Phase III data; approved in the U.S.

In an ongoing Phase III study of 653 patients receiving Kaletra or Pfizer Inc.'s Viracept nelfinavir in combination with BioChem Pharma Inc.'s Epivir lamivudine ( 3TC) and Bristol-Myers Squibb Co....